Role of immune cells in animal models for inherited peripheral neuropathies

NeuroMolecular Medicine

Volumn 8, Issue 1-2, 2006, Pages 175-189

  Wang Ip, Chi ^a   Kroner, Antje ^a   Fischer, Stefan ^a   Berghoff, Martin ^a   Kobsar, Igor ^a   Mäurer, Mathias ^a   Martini, Rudolf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Axonopathy; Demyelination; Endoneurial fibroblasts; Lymphocytes; Macrophages; Myelin; Myelin phagocytosis

Indexed keywords

CYTOKINE; MYELIN;

CD8+ T LYMPHOCYTE; DEMYELINATING NEUROPATHY; DEMYELINATION; DISEASE MODEL; ELECTRON MICROSCOPY; FIBROBLAST; GENETIC DISORDER; HEREDITARY MOTOR SENSORY NEUROPATHY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MACROPHAGE; NEUROPATHY; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CONNEXINS; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; GENES, RAG-1; HUMANS; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, GENETIC; MYELIN P0 PROTEIN; MYELIN PROTEINS; MYELIN SHEATH; PERIPHERAL NERVOUS SYSTEM DISEASES;

ANIMALIA;

EID: 33745235797     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:8:1:175     Document Type: Review

References (82)

1. Adlkofer K., Martini R., Aguzzi A., Zielasek J., Toyka K. V., and Suter U. (1995) Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nature Genet. 11, 274-280.
2. Angelov D. N., Waibel S., Guntinas-Lichius O., et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 100, 4790-4795.
3. Anzini P., Neuberg D. H. H., Schachner M., et al. (1997) Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J. Neurosci. 17, 4545-4551.
4. Ballin R. H., Thomas P. K. (1969) Electron microscope observations on demyelination and remyelination in experimental allergic neuritis. I. Demyelination. J. Neurol. Sci. 8, 1-18.
5. Bandtlow C. E., Heumann R., Schwab M. E., Thoenen H. (1987) Cellular localization of nerve growth factor synthesis by in situ hybridization. EMBO J. 6, 891-899.
6. Barde Y. A. (1989) Trophic factors and neuronal survival. Neuron. 21, 1525-1534.
7. Berger J., Moser H. W., and Forss-Petter S. (2001) Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr. Opin. Neurol. 14, 305-312.
8. Berghoff M., Samsam M., Muller M., et al. (2005) Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol. Cell Neurosci. 28, 118-127.
9. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., and Grubeck-Loebenstein B. (2004) How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3, 169-176.
10. Blum D., Chtarto A., Tenenbaum L., Brotchi J., and Levivier M. (2004) Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17, 359-366.
11. Carenini S., Mäurer M., Werner A., et al. (2001) The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in P0. J. Cell Biol. 152, 301-308.
12. Frei R., Mötzing S., Kinkelin I., Schachner M., Koltzenburg M., and Martini R. (1999) Loss of distal axons and sensory Merkel cells and features indicative of muscle denervation in hindlimbs of P0-deficient mice. J. Neurosci. 19, 6058-6067.
13. Giese K. P., Martini R., Lemke G., Soriano P., and Schachner M. (1992) Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71, 565-576.
14. Gold R., Stoll G., Kieseier B. C., Hartung H-P., and Toyka K. V. (2005) Experimental autoimmune neuritis. In: Dyck P.J., Thomas P.K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 609-633.
15. Hald A. and Lotharius J. (2005) Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol. 193, 279-290.
16. Hartung H-P., Kieseier B. C., Gold R., Stoll G., and Toyka K. V. (2005) Introduction into immune reactions in the peripheral nervous system. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 559-572.
17. Hartung H. P. and Kieseier B. C. (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107, 140-147.
18. Hartung H. P., Stoll G., and Toyka K. V. (1993) Immune reactions in the peripheral nervous system. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, 3rd Edition, pp. 418-444. Philadelphia: Saunders Comp.
19. Hartung H. P., Gold R., and Jung S. (1998) Local immune responses in the peripheral nervous system. In: Antel J., Birnbaum J., Hartung H. P. (eds), Clinical Neuroimmunology, Oxford: Blackwell Science, pp. 40-54.
20. Hauben E., Butovsky O., Nevo U., et al. (2000) Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 20, 6421-6430.
21. Heumann R., Korsching S., Bandtlow C., and Thoenen H. (1987a) Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J. Cell Biol. 104, 1623-1631.
22. Heumann R., Lindholm D., Bandtlow C., et al. (1987b) Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: Role of macrophages. Proc. Natl. Acad. Sci. USA 84, 8735-8739.
23. Ho T. W., McKhann G. M., and Griffin J.W. (1998) Human autoimmune neuropathies. Ann. Rev. Neurosci. 21, 187-226.
24. Hohlfeld R., Kerschensteiner M., Stadelmann C., Lassmann H., and Wekerle H. (2000) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J. Neuroimmunol. 107, 161-166.
25. Huxley C., Passage E., Manson A., et al. (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum. Mol. Gent. 5, 563-569.
26. Huxley C., Passage E., Robertson A. M., et al. (1998) Correlation between varying levels and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum. Mol. Genet. 7, 449-458.
27. Ito M, Blumberg B. M., Mock D. J., et al. (2001) Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J. Neuropathol. Exp. Neurol. 60, 1004-1019.
28. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., and Hohlfeld R. (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann. Neurol. 53, 292-304.
29. Kerschensteiner M., Gallmeier E., Behrens L., et al. (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189, 865-870.
30. Kieseier B. C., Clements J. M., Pischel H. B., et al. (1998) Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome. Ann. Neurol. 43, 427-434.
31. Kim S. U. and de Vellis J. (2005) Microglia in health and disease. J. Neurosci. Res. 81, 302-313.
32. Kobsar I., Mäurer M., Ott T., and Martini R. (2002) Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32. Neurosci. Lett. 320, 17-20.
33. Kobsar I., Hasenpusch-Theil K., Wessig C., Müller H. W., and Martini R. (2005) Evidence for macrophage-mediated myelin disruption in an animal model for CMT1A. J. Neurosci. Res. 81, 857-864.
34. Kobsar I., Berghoff M., Samsam M., et al. (2003) Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126, 804-813.
35. Lampert P. W. (1969) Mechanism of demyelination in experimental allergic neuritis. Lab Invest 20, 127-138.
36. Lindholm D., Heumann R., Hengerer B., and Thoenen H. (1988) Interleukin I increases stability and transcription of mRNA encoding nerve growth factor in cultured rat fibroblasts. J. Biol. Chem. 263, 16,348-16,351.
37. Low P. A. (1977) The evolution of 'onion bulbs' in the hereditary hypertrophic neuropathy of the Trembler mouse. Neuropath. Appl. Neurobiol. 3, 81-92.
38. Lupski J. R. and Chance P. F. (2005) Hereditary motor and sensory neuropaties involving altered dosage or mutation of PMP22: The CMT1A duplication and HNPP deletion. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, 4th Edition, Philadelphia: Elsevier Saunders, pp. 1659-1680.
39. Lupski J. R., Montes de Oca-Luna R., et al. (1991) DNA duplication associated with Charcot-Marie-Tooth disease Type 1A. Cell 66, 219-232.
40. Magyar J. P., Martini R., Ruelicke T., et al. (1996) Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16, 5351-5360.
41. Martini R. (1997) Animal models for inherited peripheral neuropathies. J. Anat. 191, 321-336.
42. Martini R. (2005) Transgenic models of nerve degeneration. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 535-556.
43. Martini R. and Toyka K. V. (2004) Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol. 3, 457-465.
44. Martini R., Zielasek J., Toyka K. V., Giese K. P., and Schachner M. (1995) Protein zero (PO)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nature Genet. 11, 281-286.
45. Mäurer M., Kobsar I., Berghoff M., Schmid C. D., Carenini S., and Martini R. (2002) Role of immune cells in animal models for inherited neuropathies: facts and visions. J. Anat. 200, 405-414.
46. Mäurer M., Müller M., Kobsar I., Leonhard C., Martini R., and Kiefer R. (2003) Origin of pathogenic macrophages and endoneurial fibroblast-like cells in an animal model of inherited neuropathy. Mol. Cell Neurosci. 23, 351-359.
47. Mäurer M., Schmid C. D., Bootz F., et al. (2001) Bone marrow transfer from wild type mice reverts the beneficial effect of genetically-mediated immune deficiency in myelin mutants. Mol. Cell Neurosci. 17, 1094-1101.
48. Moalem G., Gdalyahu A., Shani Y., et al. (2000) Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J. Autoimmun. 15, 331-345.
49. Mombaerts P., Iacomini J., Johnson R. S., Herrup K., Tonegawa S., and Papaioannou V. E. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869-877.
50. Nagatsu T. and Sawada M. (2005) Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11, 999-1016.
51. Niemann S., Sereda M. W., Rossner M., et al. (1999) The "CMT rat" peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22. Ann. NY Acad. Sci. 883, 254-261.
52. Perea J., Robertson A., Tolmachova T., et al. (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum. Mol. Genet. 10, 1007-1018.
53. Raeymaekers P., Timmerman V., Nelis E., et al. (1991) Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1, 93-97.
54. Robertson A. and Huxley C. (2005) Transgenic models of inherited neuropathy. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 1561-1583.
55. Robertson A. M., Perea J., McGuigan A., et al. (2002) Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J. Anat. 200, 377-390.
56. Samsam M., Frei R., Marziniak M., Martini R., and Sommer S. (2002) Impaired sensory function in heterozygous PO knockout mice is associated with nodal changes in sensory nerves. J. Neurosci. Res. 67, 167-173.
57. Samsam M., Mi W., Wessig C., et al. (2003) The wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J. Neurosci. 23, 2833-2839.
58. Sargsyan S.A., Monk P. N., and Shaw P.J. (2005) Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51, 241-253.
59. Scherer S. S., Kleopa K. A. (2005) X-linked Charcot-Marie-Tooth disease. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 1791-1804.
60. Scherer S. S., Xu Y-T., Nelles E., Fischbeck K., Willecke K., and Bone L. J. (1998) Connexin32-null mice develop demyelinating peripheral neuropathy. Glia 24, 8-20.
61. Schmid C. D., Stienekemeier M., Oehen S., et al. (2000) Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J. Neurosci. 20, 729-735.
62. Schwartz M. (2001) Protective autoimmunity as a T-cell response to central nervous system trauma: prospects for therapeutic vaccines. Prog. Neurobiol. 65, 489-496.
63. Sereda M., Griffiths I., Pühlhofer A., et al. (1996) A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16, 1049-1060.
64. Shy M. E. (2005) Hereditary motor and sensory neuropathies related to MPZ (PO) mutations. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 1681-1706.
65. Shy M. E., Garbern J. Y., Kamholz J. (2002) Hereditary motor and sensory neuropathies: a biological perspective. Lancet. Neurol. 1, 110-118.
66. Shy M. E., Lupski J. R., Chance P. F., Klein C. J., and Dyck P. J. (2005) Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, 4th Edition, Philadelphia: Elsevier Saunders. pp. 1623-1653.
67. Shy M. E., Arroyo E., Sladky J., et al. (1997) Heterozygous P0 knock-out mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy. J. Neuropath. Exp. Neurol. 56, 811-821.
68. Stoll G. and Müller H. W. (1999) Nerve injury, axonal degeneration and neural regeneration: basic insights. Brain Pathol. 9, 313-325.
69. Stuchbury G. and Munch G. (2005) Alzheimer's associated inflammation, potential drug targets and future therapies. J Neural. Transm. 112, 429-453.
70. Suter U. and Scherer S. S. (2003) Disease mechanisms in inherited neuropathies. Nat. Rev. Neurosci. 4, 714-726.
71. Suter U. and Martini R. (2005) Myelination. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 411-431.
72. Taskinen H. S., Roytta M. (2000) Increased expression of chemokines (MCP-1, MIP-1alpha, RANTES) after peripheral nerve transection. Peripher. Nerv. Syst. 5, 75-81.
73. Teitelbaum S. L. (2000) Bone resorption by osteoclasts. Science 289, 1504-1508.
74. Toews A. D., Barrett C., and Morell P. (1998) Monocyte chemoattractant protein 1 is responsible for macrophage recruitment following injury to sciatic nerve. J. Neurosci. Res. 53, 260-267.
75. Tofaris G. K., Patterson P. H., Jessen K. R., and Mirsky R. (2002) Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J. Neurosci. 22, 6696-6703.
76. Topilko P., Schneider-Maunoury S., Levi G., et al. (1994) Krox-20 controls myelination in the peripheral nervous system. Nature 371, 796-799.
77. Warner L. E. and Lupski J. R. (2005) Hereditary motor and sensory neuropathy related to early growth response 2 (EGR2) gene. In: Dyck P. J., Thomas P. K. (eds), Peripheral Neuropathy, Philadelphia: Elsevier Saunders, pp. 1707-1715.
78. Young P. and Suter U. (2001) Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res. Rev. 36, 213-221.
79. Young P. and Suter U. (2003) The causes of Charcot-Marie-Tooth disease. Cell Mol. Life Sci. 60, 2547-2560.
80. Zielasek J., Martini R., and Toyka K. V. (1996) Functional abnormalities in P0-deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 19, 946-952.
81. Zielasek J., Jung S., Gold R., Liew F. Y., Toyka K. V., and Hartung H. P. (1995) Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58, 81-88.
82. Zlokovic B. V. (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28, 202-208.